Spectris (SXS) Q3 2024 TU earnings summary

Executive summary

• Order intake and sales declined year-over-year, with Q3 2024 sales down 13% and order intake down 10%, but trends have stabilized compared to the first half.

• Market softness persists in China, pharma, and academia, expected to continue into early 2025.

• October saw a meaningful uptick in order intake, signaling potential recovery.

• Strategic acquisitions (Micromeritics, SciAps, Piezocryst) and ERP implementation are progressing well.

• Accelerated cost reduction and a profit improvement program targeting £50 million in annualized benefits are underway.

Financial highlights

• Adjusted operating profit for the full year is expected to be around £200 million, including acquisitions.

• Net debt stood at £393 million at period end.

• Group leverage (net debt/EBITDA) is projected at the upper end of the 1–2x target range if Piezocryst acquisition completes.

• Group reported sales fell to £302.7 million in Q3 2024 from £349.1 million in Q3 2023; LFL sales down 10%.

• Foreign exchange and disposals net of acquisitions reduced sales by 2% and 1%, respectively.

Outlook and guidance

• Market headwinds in China, pharma, and academia are likely to persist into at least Q1 2025.

• Order book at end of Q3 was over £530 million, providing about 4.5 months of order cover.

• Guidance for 2024 has been revised down, reflecting a balanced risk-adjusted approach.

• Profit improvement and restructuring programs expected to deliver £50 million run rate benefits, with £15–20 million costs in 2024 and £20–25 million in 2025.